Olmesartan medoxomil/amlodipine

Drug Profile

Olmesartan medoxomil/amlodipine

Alternative Names: Azor; CS-8663; Ol-Vamlo; Olmersartan medoxomil/amlodipine besilate; Sevikar

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Inc
  • Developer Daiichi Sankyo Inc; Sun Pharmaceutical Industries
  • Class Antihypertensives; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 17 Nov 2016 Generic equivalent available in USA for Hypertension
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in China (PO, Tablet)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top